Evaluation and Validation of New Biomarkers by Mass Spectrometry

The investigators will perform biochemical and metabolic evaluations on cord blood, venous blood of the mother and urine of the foetus and mother using time-of-flight and tandem mass spectrometry. The investigators could evaluate, dose and validate gestational diabetes mellitus biomarkers of the fetus and mother.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

1 day and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre de recherche clinique Etienne-Le Bel du CHUS

Sherbrooke, Quebec, J1H 5N4, Canada

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For women:

Aged 18 or more
24 weeks of gestation or more
Type 1, type 2 or gestational diabetes mellitus for group 1
Without diabetes for group 2.

For newborn:

37 weeks of gestation or more
Birth weight 2500 g or more

Exclusion criteria

Multiple birth

Treatment and study plan

Primary outcomes

Foetal HbA1c

Time frame: At delivery

Secondary outcomes

Foetal acetylated Hb

Time frame: At delivery

Sponsors and collaborators

Lead sponsor

Université de Sherbrooke

Other

Registry information

Official study title

A New Approach by Mass Spectrometry for Evaluation and Validation of New Biomarkers of Fetus and Mother

Acronym: DG7

Important dates

Study start: 2009
Primary completion: 2011
Study completion: 2013
First posted: Dec 4, 2009
Registry last updated: May 8, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed